3-Hpdroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are es
tablished drugs for the treatment of hypercholesterolemia, but several stud
ies have shown that benefits obtained with these drugs are not causally rel
ated only to regression of cholesterol lowering. Moreover, in experimental
models of progressive renal disease, statins have reduced the extent of glo
merulosclerosis, This study evaluated the antiproteinuric effect of a daily
dose of 40 mg fluvastatin for 6 months in moderately proteinuric patients
with immunoglobulin A nephropathy, stable renal function, and no indicators
of poor long-term prognosis, The effects of therapy were evaluated on the
basis of 24-hour proteinuria (total proteinuria and alburninuria), albumine
mia, creatinine clearance, cholesterol, and triglyceride values. Renal func
tion remained stable in all patients. A significant decrease in proteinuria
was observed after 6 months of therapy and persisted for all the observati
ons, An increase in serum albumin was observed after 6 months of therapy. T
his study suggests that there is an antiproteinuric effect of HMG-CoA reduc
tase inhibitors in moderately proteinuric patients with immunoglobulin A ne
phropathy.